Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US EUA For Lilly’s Bamlanivimab Conditioned On Additional GMP Compliance Requirements

Executive Summary

Letter of authorization for COVID-19 therapeutic made at troubled Lilly plant requires independent third-party oversight.

You may also be interested in...



US Buy Of Lilly’s COVID-19 Therapy Now Turns On FDA's Manufacturing Quality Assessment

Under pressure to authorize use of Lilly’s bamlanivimab, the FDA must first weigh efficacy signals and GMP plant remediation progress.

Can We Talk? US FDA Remote Records Review Missteps Worry Industry

Alkermes CRL is just the latest fallout from black-hole process.

Global Benchmarking Data Offer Path To Improved Drug Manufacturing Quality

Prospective new participants in benchmarking study must share manufacturing plant data by 20 November to see how they measure on quality against industry peers.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel